Articles

Addition of daratumumab to ixazomib/dexamethasone in second-line post-lenalidomide relapsed multiple myeloma (phase 1 portion of the ongoing DARIA study) resulted in a >70% overall response rate. Read More ›

Adding isatuximab to pomalidomide-dexamethasone treatment in RRMM patients with preexisting plasmacytomas resulted in improved median progression-free survival and rates of overall response and very good partial response with a manageable safety profile. Read More ›

A retrospective analysis of ICARIA-MM and TCD14079 studies shows adding isatuximab to pomalidomide-dexamethasone improved progression-free survival and increased rates of overall response and very good partial response or better in patients with gain(1q21). Read More ›

Adding elotuzumab to bortezomib/lenalidomide/dexamethasone as induction therapy for newly diagnosed multiple myeloma patients in the GMMG-HD6 study failed to increase the rates of very good partial response and complete response after 4 cycles. Read More ›

Pragmatic setting administration of the all-oral combination of pomalidomide plus cyclophosphamide/dexamethasone (POMCIDEX) is a manageable, effective treatment option for patients with relapsed/refractory multiple myeloma. Read More ›

In newly diagnosed transplant-eligible multiple myeloma patients who achieved very good partial response or better in the Italian FORTE study, there was strong concordance among 3 minimal residual disease–assessing techniques. Read More ›

Post-induction ixazomib as maintenance therapy in patients newly diagnosed with multiple myeloma not treated with front-line stem-cell transplantation (TOURMALINE-MM4 trial) resulted in median progression-free survival of 17.4 months with tolerable safety. Read More ›

In the GMMG-Concept trial, the addition of isatuximab to carfilzomib/lenalidomide/ dexamethasone in newly diagnosed high-risk patients with multiple myeloma led to an approximately 90% rate of very good partial response or better with manageable toxicity. Read More ›

Efficacy and toxicity outcome measures with daratumumab added to carfilzomib/dexamethasone were consistent across subgroups within the CANDOR trial, regardless of lenalidomide- or bortezomib-refractory status or number of previous treatments. Read More ›

Idecabtagene vicleucel resulted in an overall response rate of 73% and demonstrated a tolerable safety profile in heavily pretreated patients who were refractory to their last regimen in the KarMMa trial. Read More ›